|
|
| 亞旭所代理的MedChemExpress (MCE) 提供多元的高品質研究化學品和生物化學品，包括用於實驗室和科學用途的新型生物活性化合物、染劑、胜肽和天然化合物。 |
|
• 超過 30,000 種生物活性分子化合物的庫存
|
|
|
• 超過針對20多種信號通路中的500多種關鍵目標蛋白的化合物
|
|
• 產品均附上品質報告書（LC/MS、NMR 和 HPLC）
|
|
• 每月發布超過500 種最新的產品
|
|
• 提供詳細Datasheet的資訊
|
|
|
• 高純度和有競爭力的價格
|
|
|
• 快速到貨
|
|
|
|
CAS No.: 1592908-75-2
|
|
|
|
|
Research Area:
Bax/Bak Inhibitor/Acute and Chronic Degenerative Diseases
|
|
|
|
•
|
Potent Bax/Bak oligomerization inhibitor that prevents mitochondrial outer membrane permeabilization (MOMP).
|
|
•
|
Prevents genotoxic cell death and promotes neuroprotection.
|
|
|
|
Solubility: DMSO : 200 mg/mL (290.44 mM; Need ultrasonic)
|
|
|
|
CAS No.: 2377858-38-1
|
|
|
|
|
Research Area: NHEJ Inhibitor/Leukaemia
|
|
|
|
•
|
SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor and inhibits the end-joining of DNA in a Ligase IV-dependent manner.
|
|
•
|
Induces cell apoptosis and has anticancer activity.
|
|
|
|
Solubility: DMSO : 100 mg/mL (239.06 mM; Need ultrasonic and warming)
|
|
|
|
CAS No.: 1582289-91-5
|
|
|
|
|
Research Area: PAI-1 Inhibitor/Glioblastoma
|
|
|
|
•
|
Potent, orally active PAI-1 inhibitor with anti-glioblastoma and immunomodulatory effects.
|
|
•
|
Can cross the blood-brain barrier and inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to STAT3.
|
|
•
|
Exerts synergistic effects in combination with Cisplatin by inhibiting PI3K/AKT pathway in glioma.
|
|
|
|
Solubility: DMSO : 100 mg/mL (244.22 mM; ultrasonic and warming to 60°C)
H2O : 100 mg/mL (244.22 mM; Need ultrasonic)
|
|
|
|
|
|
|
Research Area: SOS1/KRAS Interaction Inhibitor/KRAS-Driven Cancer
|
|
|
|
•
|
Peptide-based SOS1/KRAS protein interaction inhibitor and binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM).
|
|
•
|
Directly inhibits nucleotide association to KRAS, impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
|
|
|
|
Solubility: H2O : 33.33 mg/mL (14.48 mM; Need ultrasonic)
|
|
|
|
CAS No.: 101303-98-4
|
|
|
|
|
Research Area: 5-HT3 Receptor Antagonist/Schizophrenia
|
|
|
|
•
|
Highly potent 5-HT3 receptor antagonist with Kis of 0.38 nM and 373 nM for 5-HT3 receptor and 5-HT4 receptor, respectively.
|
|
•
|
Moderate IK1 channel agonist, exerts significant antiarrhythmic and cardiac protective effects.
|
|
|
|
Solubility: DMSO : 100 mg/mL (288.81 mM; Need ultrasonic)
|
|
|
|
Cytotoxicity LDH Assay Kit
|
|
|
|
|
細胞死亡或細胞膜膜損傷造成細胞膜失去其完整性會導致細胞質enzyme的釋放， 因此可以透過測量釋放到培養上清液中enzyme的活性來測量急性細胞毒性。
乳酸脫氫酶(LDH) 是一種穩定的enzyme，存在於所有細胞類型中，並在細胞膜受損後迅速釋放到細胞培養基中。
MCE Cytotoxicity LDH Assay Kit 可以檢測培養上清液中的 LDH 活性，可以說是測量細胞毒性的指標。
|
|
|
|
|
|
|
|
MCE Anti-Liver Cancer Compound Library/MCE Rare Diseases Drug Library
|
|
|
|
|
Library
|
Description
|
|
MCE Anti-Liver Cancer Compound Library
|
提供超過1,300 多種具有已證實和具有潛力抗肝癌的化合物，可用於抗肝癌藥物篩选和相關研究。
標靶RAF/MEK/ERK路徑、PI3K/AKT/mTOR路徑、WNT/B-catenin路徑、insulin-like growth factor路徑、C-met/HGFR路徑等訊息傳遞路徑。
|
|
MCE Rare Diseases Drug Library
|
提供超過1500種用於罕見病治療的藥物，為罕見病提供相對應適應症。新適應症的藥物再利用能省時、省錢、成功率提高，大大降低了罕見病藥物開發的風險。MCE Rare Diseases Drug Library是研究罕見疾病中的最強大好用的工具。
|
|
|
|
|
|
|
|
|
|
|
|
|
